News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Atossa Genetics, Inc. to Present at Biotech Showcase 2012


12/28/2011 8:54:21 AM

SEATTLE, WA--(Marketwire - December 27, 2011) -

Atossa Genetics, Inc. announced today that Steven C. Quay, M.D., Ph.D., FCAP, Chairman, President & CEO of Atossa Genetics, Inc. and Director of the National Reference Laboratory for Breast Health, will be presenting at the Biotech Showcase 2012 conference, which will take place from January 9-11 in San Francisco. Dr. Quay's presentation will be webcast via Atossa's website, www.atossagenetics.com, on Tuesday, January 10, 2012, beginning at 11:45 a.m. Pacific Time (2:45 p.m. Eastern Time).

"This is an exciting time at Atossa as we have recently launched the ForeCYTE Breast Health Test(sm) for breast cancer risk assessment and the ArgusCYTE Breast Health Test(sm), the only circulating breast tumor cell test available today that identifies mRNA expression levels for estrogen receptors, progesterone receptor, and HER-2 antigen in a single blood draw," stated Dr. Quay. "I am pleased to have this opportunity to tell investors about our company, our suite of products and services, and our growth opportunities."

Breast cancer is a disease that typically develops in stages over an approximately eight-year period. Although current mammography procedures can detect cancer already present in the breast, the ForeCYTE Breast Health Test(sm), by testing samples of nipple aspirate fluid collected from the milk ducts and lobules of the breast, can identify pre-cancerous cellular changes that heighten the risk for breast cancer, empowering doctors and their patients to consider measures such as lifestyle changes and medical treatments that may prevent breast cancer from developing or treat breast cancer earlier, if it develops.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. is a privately held health care company based in Seattle, Washington, that provides a comprehensive set of innovative breast health evaluation products and services that provide accurate and actionable results for personalized cancer prevention and breast health. Atossa has established the National Reference Laboratory for Breast Health, a specially equipped, CLIA-registered laboratory located in Seattle that provides comprehensive test results to guide personalized breast cancer prevention and treatment solutions. Patients, health care providers, investors and others seeking information on Atossa and its products and services should visit www.atossagenetics.com. For information on the ForeCYTE Breast Health Test(sm) or the ArgusCYTE Breast Health Test(sm), please visit http://nrlbh.com/testing-services/risk-assessment.php or call or 800-351-3902.


Contacts:

Steven C. Quay, M.D., Ph.D., FCAP (Corporate)
Chairman, President and CEO of Atossa Genetics and Director of the National Reference Laboratory for Breast Health
206-325-6086
Email Contact

Matthew D. Haines (Investors and Media)
Managing Director
MBS Value Partners
212-710-9686
Email Contact

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES